Constellium (CSTM) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
15 Oct, 2026Executive summary
FY 2023 Adjusted EBITDA reached a record €713 million, up 6% YoY; Free Cash Flow was €170 million and net income was €129 million.
Q4 Adjusted EBITDA rose 15% YoY to €171 million despite lower shipments and revenue; Free Cash Flow was €58 million.
Net debt declined to €1.664 billion and leverage to 2.3x at year-end, a multi-year low.
Financial highlights
FY revenue was €7.239 billion, down 11% YoY; shipments fell 6% to 1.5 million tons, while VAR rose 7% to €2.924 billion.
FY net income was €129 million versus €308 million; gross profit rose to €710 million from €672 million, and operating income was €337 million versus €334 million.
Q4 revenue was €1.613 billion, down 13% YoY; shipments were 336 thousand tons, down 9%, and VAR was €681 million, down 2%.
Q4 net income was €11 million versus €30 million; Adjusted EBITDA was €171 million versus €148 million in Q4 2022.
FY diluted EPS was €0.84 versus €2.06; basic EPS was €0.85 versus €2.10.
Outlook and guidance
2024 Adjusted EBITDA guidance is €740–770 million, excluding non-cash metal price lag; net income reconciliation cannot be forecast without unreasonable efforts.
2024 Free Cash Flow is expected to exceed €130 million; capex is €370 million, cash interest ~€125 million, cash taxes ~€55 million, and TWC/Other is expected to use modest cash.
The 2025 target is Adjusted EBITDA above €800 million; target leverage range is 1.5x–2.5x.
Q1 2024 is expected to be weaker, partly due to January extreme cold and snow affecting Muscle Shoals operations.
Inflationary pressures are expected to continue at more moderate levels; 2024 energy is largely secured at more favorable levels than 2023 but remains above historical averages.
Latest events from Constellium
- Record Q3 Adjusted EBITDA of $276 million lifted FY 2026 guidance.CSTM
Q3 2026 - Record Q2 and H1 results, raised 2026 guidance, and strong segment-driven profit growth.CSTM
Q2 2026 - Record Adjusted EBITDA and net income, with raised 2026 outlook and strong liquidity.CSTM
Q1 2026 - Director appointments, executive pay, and share repurchase authorizations recommended for approval.CSTM
Proxy filing - Shareholders will vote on director appointments, executive pay, financials, and share repurchases.CSTM
Proxy filing - Shareholders to vote on director appointments, executive pay, and share repurchase plans after a strong 2025.CSTM
Proxy filing - Record 2025 results, strong cash flow, reduced leverage, and Vision 2028 launched.CSTM
Q4 2025 - Q2 2024: Net income rose, cash flow strong, Swiss flooding paused guidance, 2025 target reaffirmed.CSTM
Q2 2024 - Revenue up 5% and net income up 73% in Q1 2025, with guidance reaffirmed.CSTM
Q1 2025